ArticleInternational journal of clinical oncology2019
Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.
Article in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Risks of second non-breast primaries following breast cancer in women: a systematic review and meta-analysis.Breast cancer research : BCR · 2023Pooled it
- Risk assessment of secondary primary malignancies: results from two large prospective European cohorts.NPJ precision oncology · 2026Article
- Challenging and Successful Therapy Decision-Making for AML Post Cytotoxic Therapy and Concomitant Active Breast Cancer - A Case Report and Experience-Driven Strategy.Breast cancer (Dove Medical Press) · 2026Article
- Risk of second primary malignancies in prostate cancer patients: A Surveillance, Epidemiology, and End Results population-based study.Asian journal of urology · 2026Article
- Breast cancer as the first primary malignancy: clinical pathological characteristics of common cancer combinations.Discover oncology · 2025Review
- Risk factors of breast cancer patients developing multiple primary cancers: a retrospective study and establishing/testing of machine learning models.BMC medical informatics and decision making · 2025Article
- Association of different treatment modalities for rectal cancer and second primary urinary system neoplasms, findings from SEER.Scientific reports · 2025Article
- Occurrence of Malignancies Other than Breast and Ovarian Cancer in Female Carriers of aCancers · 2025Article
- Risk of second primary cancer in young breast cancer survivors: an important yet overlooked issue.Therapeutic advances in medical oncology · 2025Review
- Article
- The molecular chronology of mammary epithelial cell fate switching.bioRxiv : the preprint server for biology · 2024Article
- Second primary non-breast cancers in young breast cancer survivors.Breast cancer research and treatment · 2024Article
- The contribution of second primary cancers to the mortality of patients with a first primary breast cancer.Breast cancer research and treatment · 2024Article
- Association between chemotherapy for surgically treated rectal cancer and second primary endometrial cancer.Scientific reports · 2024Article
- Incidence, risk and prognosis of second primary malignancy of patients with gastric adenocarcinoma.Scientific reports · 2024Article
- Acute Myeloid Leukemia Post Cytotoxic Therapy in Breast Cancer Survivors-Over 23 Years of Single Center Analysis.Journal of clinical medicine · 2024Article
- Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.Breast cancer (Tokyo, Japan) · 2023Article
- Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer.Haematologica · 2023Article
- Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis.Frontiers in oncology · 2023Article
- Predictive models for overall survival in breast cancer patients with a second primary malignancy: a real-world study in Shanghai, China.BMC women's health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the improvement in the survival of breast cancer, developing second primary malignancy becomes a serious health issue. The aim of this study was to explore the survival of breast cancer patients with second primary malignancy, and to evaluate the impact of chemotherapy on the risk of different cancer sites.
methodObtaining data from the Surveillance, Epidemiology, and End Results database, we calculated the standardized incidence ratio (SIR) for second primary malignancy in breast cancer survivors between 2000 and 2014. Overall survival and cancer-specific survival were analyzed with Kaplan-Meier method. Then, we further conducted stratified sub-analyses according to chemotherapy.
resultsThe overall risk of second primary cancer for all sites was significantly elevated in breast cancer patients (SIR = 1.15, 95% CI 1.14-1.16). Overall survival and cancer-specific survival of the patients with breast cancer only were significantly better than the patients with multiple primary cancers (both P < 0.001). Chemotherapy was associated with increased incidences for all sites, except lymphoma, myeloma, and chronic lymphocytic leukemia (SIR = 0.80, 95% CI 0.72-0.88; SIR = 0.85, 95% CI 0.71-1.01; SIR = 0.57, 95% CI 0.43-0.74, respectively). The risk for developing second acute myeloid leukemia after chemotherapy in breast cancer patients varied with age and latency.
conclusionFemale breast cancer patients showed higher incidence of second primary malignancy, which was associated with poorer prognosis. Chemotherapy benefits should be weighed against the risks of second primary malignancy.
Indexed as
Identifiers
30888527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.